The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Determination of genomic profile to predict clinical response to FOLFOX plus bevacizumab in metastatic colorectal cancer.
T. J. George
No relevant relationships to disclose
H. Liu
No relevant relationships to disclose
L. V. Duckworth
No relevant relationships to disclose
J. E. Sullivan
No relevant relationships to disclose
J. Dong
No relevant relationships to disclose
C. Liu
No relevant relationships to disclose
L. H. Dang
No relevant relationships to disclose
K. Slentz-Kesler
Employment or Leadership Position - Almac Diagnostics
C. J. Allegra
No relevant relationships to disclose